Rating- neutral; Pharma sector- Poised for strong growth in Q1FY24
时间:2024-06-17 17:11:31 阅读(143)
We anticipate a positive performance from our pharmaceutical sector coverage in Q1FY24, driven by improved sales in the US market and strong performance across most branded markets. As the cost pressures gradually ease, we expect to see a robust y-o-y Ebitda growth of 22% (excluding BIOS and Mankind). In the hospital segment, we project a relatively stable performance compared to the previous quarter, with occupancy trends gradually returning to pre-Covid levels. For diagnostic companies, we anticipate a slight increase in non-Covid realisations per patient on a quarterly basis, supported by price hikes and higher volumes of non-Covid tests. Our top picks in the pharma sector are Sun Pharma (SUNP), Mankind, and Cipla. Although recent price increases may limit short-term upside, we maintain a positive outlook on APHS, Rainbow, and KIMS in the healthcare services sector.
Pharma: Improved US, healthy branded markets, yoy margin expansion in store
Hospitals: Steady quarter in store We expect a sequentially steady performance for the India-based hospitals, with lower occupancies being offset by higher ARPOB. For hospitals, we forecast a topline growth of 15% y-o-y in Q1FY24. Overall, we expect an Ebitda growth of 20% y-o-y for our hospitals.
Diagnostics: We expect an uptick in B2C sales growth
Regarding the diagnostic firms, we anticipate a slight increase in non-Covid revenue per patient q-o-q, supported by price adjustments and higher volumes of non-Covid tests. We have factored in a y-o-y growth of 8-12% in non-Covid sales for DLPL and METROHL. We expect a decrease in Covid-related sales for both compared to the last quarter. In Q1FY24, we project a 20% q-o-q Ebitda growth rate for DLPL and a 2% q-o-q growth rate for METROHL. The lower growth rate for METROHL is due to the loss of the NACO contract, which accounted for 4-5% of sales, starting from February 2023.
猜你喜欢
- Mcap of BSE-listed firms hits fresh record high of Rs 293
- Markets undergoing correction for past month, select heavyweights outperform; US markets to drive global cues
- SGX Nifty suggests gap-down start for Sensex, Nifty; 5 things to know before opening bell
- MCX Gold trend remains bullish, traders must wait for Rs 51500-51600 levels before taking long position
- SGX Nifty up- US Fed hikes rates, global markets, Q1 results, Nifty outlook; key things in focus on F&O expiry
- SGX Nifty up 1%- Nifty support, resistance, technical view, stocks under F&O ban; key things to watch out
- Mazagon Dock, JK Lakshmi Cement among 149 BSE stocks to hit 52-week highs, 19 fall to 52-week lows
- Share Market Highlights- Nifty settles below 19080, Sensex below 63880; Bank Nifty sheds over 190 points
- Markets to be guided by inflation, US interest rate scenario, geopolitical situation in FY24- Analysts